Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$166.19 USD

166.19
636,152

+2.02 (1.23%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $166.26 +0.07 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insulet Corporation [PODD]

Reports for Purchase

Showing records 301 - 320 ( 340 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 301

02/08/2012

Company Report

Pages: 6

Q4 SHOULD BE IN LINE WITH EXPECTATIONS -BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 302

11/14/2011

Industry Report

Pages: 8

Bucking Headwinds - Three Medical Device Companies To Ride Into The New Year

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 303

11/04/2011

Company Report

Pages: 3

Manufacturing Issues highlighted in Q3 shortfall All eyes on next-gen OmniPod clearance

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 304

11/04/2011

Company Report

Pages: 5

Strong Q3 Rev Growth Negatively Affected By Production Problem - BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 305

11/04/2011

Company Report

Pages: 5

Manufacturing Issues highlighted in Q3 shortfall All eyes on next-gen OmniPod clearance

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 306

11/04/2011

Company Report

Pages: 8

Respectable Q3 despite disruption, maintaining BUY but reducing PT to $18.60

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 307

11/02/2011

Company Report

Pages: 5

Expect Strong Sequential Revenue Growth

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 308

10/14/2011

Industry Report

Pages: 12

The Truffle Shuffle-Diabetes Edition: Investment Implications of Obesity on Diabetes Devices

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 309

09/30/2011

Company Report

Pages: 23

Initiating with BUY and $19.80 PT

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 75.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 310

09/02/2011

Industry Report

Pages: 9

THE EVER UNSETTLED FDA REGULATORY ENVIRONMENT

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 311

09/02/2011

Industry Report

Pages: 9

THE EVER UNSETTLED FDA REGULATORY ENVIRONMENT

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 312

08/29/2011

Industry Report

Pages: 6

BARGAIN HUNTING AMONGST THE RUBBLE

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 313

08/04/2011

Daily Note

Pages: 11

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 314

08/03/2011

Daily Note

Pages: 3

In-Line Q2-11; Banking on the next-gen OmniPod; Upgrading to Market Perform...

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 315

08/03/2011

Company Report

Pages: 5

Q2 IN LINE

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 316

08/03/2011

Company Report

Pages: 5

In-Line Q2-11; Banking on the next-gen OmniPod; Upgrading to Market Perform...

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 317

08/01/2011

Company Report

Pages: 5

Q2 Preview - BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 318

07/25/2011

Daily Note

Pages: 3

Difficult as it is, we are downgrading the stock to an UnderPerform...

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 319

07/25/2011

Company Report

Pages: 9

Difficult as it is, we are downgrading the stock to an UnderPerform...

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 320

07/25/2011

Daily Note

Pages: 12

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party